Proton radiotherapy for gynecologic neoplasms

The female reproductive tract may be the site of a wide variety of benign and malignant tumors, as well as non-neoplastic tumor-like conditions, most of which can be diagnosed by light microscopic examination including special stains and more recently immunoperoxidase techniques. Nevertheless there are situations where ultrastructural examination can contribute substantially to an accurate and specific diagnosis. It is my opinion that electron microscopy can be of greatest benefit and is most cost effective when applied in conjunction with other methodologies. Thus, I have developed an approach which has proved useful for me and may have benefit for others. In cases where it is deemed of potential value, glutaraldehyde-fixed material is obtained at the time of frozen section or otherwise at operation. Coordination with the gynecologic oncologist is required in the latter situation. This material is processed and blocked and is available if a future need arises.

Download Full-text

A Phase II Trial of Proton Radiotherapy with Chemotherapy for Nasopharyngeal Carcinoma

Journal of Neurological Surgery Part B Skull Base ◽

10.1055/s-0034-1384022 ◽

2014 ◽

Vol 75 (S 02) ◽

Author(s):

Annie Chan ◽

E. Weyman ◽

T. Goldsmith ◽

L. Wirth ◽

J. Clark ◽

...

Keyword(s):

Nasopharyngeal Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Proton Radiotherapy

Download Full-text

Proton-Radiotherapy for treatment of Hodgkin’s disease of minor or adolescent patients

10.1055/s-0040-1701886 ◽

2020 ◽

Author(s):

C Dumke ◽

S Lautenschlaeger ◽

F Eberle ◽

G Iancu ◽

M Thiemer ◽

...

Keyword(s):

Hodgkin's Disease ◽

Hodgkin’S Disease ◽

Proton Radiotherapy ◽

Adolescent Patients

Download Full-text

Development of a Multileaf Collimator for Proton Radiotherapy

10.21236/ada573178 ◽

2006 ◽

Author(s):

James McDonough ◽

Steven Avery ◽

Peter Bloch ◽

Dickson Goulart ◽

Mark Ingram ◽

...

Keyword(s):

Multileaf Collimator ◽

Proton Radiotherapy

Download Full-text

A proof of concept treatment planning study of gated proton radiotherapy for cardiac soft tissue sarcoma

Physics and Imaging in Radiation Oncology ◽

10.1016/j.phro.2021.06.001 ◽

2021 ◽

Vol 19 ◽

pp. 78-84

Author(s):

Hyeri Lee ◽

Jennifer Pursley ◽

Hsiao-Ming Lu ◽

Judith Adams ◽

Thomas DeLaney ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Treatment Planning ◽

Proof Of Concept ◽

Proton Radiotherapy ◽

Planning Study

Download Full-text

Dosimetric uncertainty in prostate cancer proton radiotherapy

Medical Physics ◽

10.1118/1.2982242 ◽

2008 ◽

Vol 35 (11) ◽

pp. 4800-4807 ◽

Cited By ~ 10

Author(s):

Liyong Lin ◽

Carlos Vargas ◽

Wen Hsi ◽

Daniel Indelicato ◽

Roelf Slopsema ◽

...

Keyword(s):

Prostate Cancer ◽

Proton Radiotherapy

Download Full-text

An Emerging Anti-p16 Antibody-BC42 Clone as an Alternative to the Current E6H4 for Use in the Female Genital Tract Pathological Diagnosis: Our Experience and a Review on p16ink4a Functional Significance, Role in Daily-Practice Diagnosis, Prognostic Potential, and Technical Pitfalls

Diagnostics ◽

10.3390/diagnostics11040713 ◽

2021 ◽

Vol 11 (4) ◽

pp. 713

Author(s):

Giuseppe Angelico ◽

Angela Santoro ◽

Frediano Inzani ◽

Patrizia Straccia ◽

Saveria Spadola ◽

...

Keyword(s):

Female Genital Tract ◽

Daily Practice ◽

Cervical Squamous Cell Carcinoma ◽

High Grade ◽

The Novel ◽

Medical Systems ◽

Ovarian Carcinomas ◽

Study Results ◽

Diagnostic Applications ◽

Gynecologic Neoplasms

Background: To date, useful diagnostic applications of p16 IHC have been documented in gynecological pathology both for HPV-related and non-HPV-related lesions. In the present article, we reported our experience with the novel anti-p16 INK4a antibody (clone BC42), whose expression was tested across all different gynecologic neoplasms; we also compared it to the traditional E6H4 clone. Moreover, we discussed and explored all the diagnostic applications of p16 IHC in gynecologic pathology. Methods: Consultation cases covering a 5-year period (2016–2020) regarding gynecological neoplastic and non-neoplastic lesions in which immunohistochemistry for p16, clone E6H4 was originally performed, were retrospectively retrieved from the files of our institution. Immunohistochemical staining for p16ink4a (BC42) [Biocare Medical group-Paceco USA; Bioptica Milan] and p16ink4a (E6H4) [Ventana Medical Systems-Arizona USA; Roche] was performed by using the Ventana automated immunostainer (Ventana Medical Systems, Tucson, AZ, USA). The immunostaining pattern was defined as negative, focal/patchy, or diffuse. Results: A total of 196 cases, represented by 36 high-grade SIL/CIN3 of the uterine cervix, 30 cervical adenocarcinomas, 22 cervical squamous cell carcinoma, 70 endometrial carcinomas, 25 high grade serous ovarian carcinomas, 6 uterine adenomatoid tumors, and 10 uterine leiomyosarcomas were included in this study. Results showed concordant staining quality of both clones on all tested neoplastic tissues. Conclusions: The novel anti-p16 antibody (BC42 clone) appeared as an alternative to the current E6H4 for use in gynecological neoplasms, offering similar levels of positivity and equally reliable staining results.

Download Full-text

Effects of deep inspiration breath hold on prone photon or proton irradiation of breast and regional lymph nodes

Scientific Reports ◽

10.1038/s41598-021-85401-4 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Bruno Speleers ◽

Max Schoepen ◽

Francesca Belosi ◽

Vincent Vakaet ◽

Wilfried De Neve ◽

...

Keyword(s):

Lung Cancer ◽

At Risk ◽

Lymph Node ◽

Organs At Risk ◽

Lymph Node Status ◽

Breath Hold ◽

Deep Inspiration ◽

Proton Radiotherapy ◽

Regional Lymph Nodes ◽

Deep Inspiration Breath Hold

AbstractWe report on a comparative dosimetrical study between deep inspiration breath hold (DIBH) and shallow breathing (SB) in prone crawl position for photon and proton radiotherapy of whole breast (WB) and locoregional lymph node regions, including the internal mammary chain (LN_MI). We investigate the dosimetrical effects of DIBH in prone crawl position on organs-at-risk for both photon and proton plans. For each modality, we further estimate the effects of lung and heart doses on the mortality risks of different risk profiles of patients. Thirty-one patients with invasive carcinoma of the left breast and pathologically confirmed positive lymph node status were included in this study. DIBH significantly decreased dose to heart for photon and proton radiotherapy. DIBH also decreased lung doses for photons, while increased lung doses were observed using protons because the retracting heart is displaced by low-density lung tissue. For other organs-at-risk, DIBH resulted in significant dose reductions using photons while minor differences in dose deposition between DIBH and SB were observed using protons. In patients with high risks for cardiac and lung cancer mortality, average thirty-year mortality rates from radiotherapy-related cardiac injury and lung cancer were estimated at 3.12% (photon DIBH), 4.03% (photon SB), 1.80% (proton DIBH) and 1.66% (proton SB). The radiation-related mortality risk could not outweigh the ~ 8% disease-specific survival benefit of WB + LN_MI radiotherapy in any of the assessed treatments.

Download Full-text